Home Contact Sitemap

PedAM

Pediatric Disease Annotations & Medicines




Disease atrial fibrillation
Phenotype C0018799|heart disease
Sentences 53
PubMedID- 23095227 Methods and results: we report 5 paroxysmal atrial fibrillation cases without any structural heart disease in which dormant thoracic vein conduction was associated with recurrent atrial tachyarrhythmias.
PubMedID- 24088003 [the use of implantable devices for long-term monitoring of cardiac rhythm after surgical treatment of atrial fibrillation in patients with ischemic heart disease].
PubMedID- 25742550 The midterm results of radiofrequency ablation and vagal denervation in the surgical treatment of long-standing atrial fibrillation associated with rheumatic heart disease.
PubMedID- 23683253 Introduction: an oral loading dose of propafenone 600 mg is used in our center as in other places around the world for conversion of recent-onset atrial fibrillation (af) in patients without structural heart disease.
PubMedID- 20417758 Efficacy of surgical ablation of atrial fibrillation in patients with rheumatic heart disease.
PubMedID- 24282904 Conclusion: overexpression of nfkappab, icam1, and vcam1 may be involved in the development and maintenance of atrial fibrillation in patients with rheumatic heart disease.
PubMedID- 21911268 The increase in sympathetic nerve density in the atrium facilitates atrial fibrillation in patients with rheumatic heart disease.
PubMedID- 22547769 Aims: the aim of this study was to determine whether altered expression and distribution of calcium- and integrin-binding protein-1 (cib1) is involved in the pathogenesis of different types of patients with atrial fibrillation (af) associated with valvular heart disease (vhd).
PubMedID- 24557149 Role of masked coronary heart disease in patients with recent-onset atrial fibrillation and troponin elevations.
PubMedID- 25216788 Introduction: there are few studies comparing the pathology of the remodeled substrate in patients of rheumatic heart disease with atrial fibrillation (af) and normal sinus rhythm (nsr).
PubMedID- 26056191 Thus, single oral doses of 600 mg propafenone appear also suitable for cardioversion of paroxysmal atrial fibrillation in patients with structural heart disease since beta-blockers are explicitly indicated in the treatment of both coronary artery disease and heart failure.
PubMedID- 21287469 New procedure for treatment of atrial fibrillation in patients with valvular heart disease.
PubMedID- 23631186 [management of atrial fibrillation comorbid with coronary heart disease].
PubMedID- 23126050 The patient was already known to have liver cirrhosis of ethylic etiology, cardiac decompensation caused by hypertensive heart disease with permanent atrial fibrillation, chronic obstructive pulmonary disease, diabetes mellitus type 2, and cholelithiasis.
PubMedID- 21584749 However, in chronic atrial fibrillation patients without structural heart disease, b-type natriuretic peptide levels did not differ between those with and without heart failure symptoms.
PubMedID- 22203918 Disputable side effects are the risk of atrial fibrillation in patients with intrinsic heart disease and increased bone loss in postmenopausal women [57, 58].
PubMedID- 24640700 [especially in the hemostatic system in geriatric patients with ischemic heart disease, complicated by persistent atrial fibrillation].
PubMedID- 22676979 Conclusions: concomitant bipolar radiofrequency ablation is an effective and safe technique for treating atrial fibrillation in patients with rheumatic heart disease undergoing valve replacement, with promising follow-up results.
PubMedID- 22263119 Background: we evaluated the efficacy of cox-maze iv procedure using bipolar irrigated radiofrequency ablation and cryothermy in chronic atrial fibrillation associated with valvular heart disease.
PubMedID- 25796343 We investigated the relationship between transient receptor potential channel subfamily m6 (trpm6) and atrial fibrosis in rheumatic heart disease patients with atrial fibrillation (af).
PubMedID- 25151145 Angiotensin ii activates signal transducers and activators of transcription 3 via rac1 in the atrial tissue in permanent atrial fibrillation patients with rheumatic heart disease.
PubMedID- 20413814 [the efficasy of atorvastatin in the case of paroxismal atrial fibrillation in patients with ischemic heart disease].
PubMedID- 20550616 Background: the purpose of this study is to evaluate the efficacy of atrial fibrillation (af) ablation in patients with moderate valvular heart disease (vhd).
PubMedID- 23110977 [25] revealed reduced approximate entropy preceding spontaneous onset of paroxysmal atrial fibrillation in patients without structural heart disease (0.89 ± 0.27 versus 1.02 ± 0.30).
PubMedID- 25766663 Early efficacy analysis of biatrial ablation versus left and simplified right atrial ablation for atrial fibrillation treatment in patients with rheumatic heart disease.
PubMedID- 21311690 The loss of short-term fractal correlation property that we found in copd subjects is related to the occurrence of several adverse clinical events such as heart failure23,25 and acute myocardial infarction.30 in addition, reduction of alpha-1 was observed before spontaneous onset of atrial fibrillation in patients without structural heart disease27 associated with vulnerability to ventricular tachycardia23,30 and ventricular fibrillation.31 exponent values lower than 0.85 were observed in patients with cardiovascular disease associated with increased mortality rate.28–30 these values are close to those found in our study (alpha-1 = 0.899) in copd patients.
PubMedID- 21960745 Increased p-wave dispersion and maximum p-wave duration predict the development of atrial fibrillation in patients with various heart diseases 9,10. sharma et al 11 reported that there was a significant decrease in parasympathetic function in patients with ibd.
PubMedID- 20937979 Electropathological substrate of longstanding persistent atrial fibrillation in patients with structural heart disease: epicardial breakthrough.
PubMedID- 22113757 Background: acute alcohol consumption can cause atrial fibrillation in patients with, and without, heart disease.
PubMedID- 22108512 Vernakalant: conversion of atrial fibrillation in patients with ischemic heart disease.
PubMedID- 23465222 Objectives: the aim of this study was to determine whether altered calreticulin expression and distribution contribute to the pathogenesis of atrial fibrillation (af) associated with valvular heart disease (vhd).
PubMedID- 22084633 The spontaneous onset of atrial fibrillation in patients without a structural heart disease is preceded by altered short-term fractal-like scaling properties of hrv (vikman et al., 1999), and the short-term scaling exponent changes toward more random direction in ectopic tachycardia reflecting disturbances in autonomic regulation or in ectopic atrial pacemakers (huikuri et al., 1999b).
PubMedID- 22291468 This agent can be considered as a first-line therapy for atrial fibrillation in patients with structural heart disease who have an ejection fraction >35% and no recent decompensated heart failure.
PubMedID- 24422171 Cmultivariate adjusted for age, new york heart association function class, ischaemic heart disease, history of hypertension and atrial fibrillation.
PubMedID- 19919968 Right to left shunt following radiofrequency catheter ablation of atrial fibrillation in a patient with complex congenital heart disease.
PubMedID- 25457137 Biphasic transthoracic cardioversion of atrial fibrillation in dogs with naturally occurring heart disease has been described in veterinary medicine and has been shown to be highly successful.
PubMedID- 23121003 Prolonged atrial effective refractory periods in atrial fibrillation patients associated with structural heart disease or sinus node dysfunction compared with lone atrial fibrillation.
PubMedID- 24431682 The indications were valvular heart disease with valve replacement, atrial fibrillation, or thrombus in 60 % patients; chronic deep vein thrombosis (dvt) in 7 % patients; thrombophilia in 9.1 % patients; recurrent pregnancy losses in 18 % patients; and dvt prophylaxis in 5.5 % patients.
PubMedID- 22354975 Management of atrial fibrillation in patients with structural heart disease.
PubMedID- 21884876 The chads2 score predicts ischemic stroke in the absence of atrial fibrillation among subjects with coronary heart disease: data from the heart and soul study.
PubMedID- 22469422 Pulmonary vein isolation for the treatment of drug-refractory atrial fibrillation in adults with congenital heart disease.
PubMedID- 25409402 Investigations: case 1: investigations showed paroxysmal atrial fibrillation with hypertensive heart disease.
PubMedID- 26519209 Inherited structural heart diseases with potential atrial fibrillation occurrence.
PubMedID- 21219558 atrial fibrillation is commonly associated with structural heart disease and is a major cause of significant cardiovascular morbidity and mortality.
PubMedID- 24755126 Objective: to compare the therapeutic warfarin and aspirin efficacies for treatments of atrial fibrillation (af) complicated with stable coronary heart disease particularly in older chinese patients.
PubMedID- 25175091 The majority of studies that aimed to study lone atrial fibrillation excluded patients with structural heart disease, but did not exclude patients with co-existing cardiovascular risk factors such as hypertension or diabetes mellitus.
PubMedID- 22056820 atrial fibrillation is commonly associated with structural heart disease, and af itself causes a sequence of complex processes of electrical, contractile, and structural remodeling of the atrial myocardium, which facilitate further af progression.
PubMedID- 20837368 Novel non-invasive p wave analysis for the prediction of paroxysmal atrial fibrillation recurrences in patients without structural heart disease: a prospective pilot study.
PubMedID- 26261514 Therefore, we hypothesized that synd4 shedding was also involved in the inflammatory response in atrial fibrillation patients with valvular heart disease.
PubMedID- 25971370 To investigate the involvement of transforming growth factor-beta1 (tgf-beta1) and tissue inhibitor of metalloproteinase 4 (timp-4) in influencing the severity of atrial fibrosis in rheumatic heart disease (rhd) patients with atrial fibrillation (af).

Page: 1 2